Hemophilia Treatment Risks

Hemophilia Treatment Risks: Antibodies

Antibodies destroy the clotting factor before it has a chance to work. This is a very serious hemophilia treatment risk because it reduces the effectiveness of the main treatment for hemophilia -- replacing clotting factors.
 
Antibodies to clotting factors develop in about 1 out of 5 people with severe hemophilia A and 1 out of 100 people with hemophilia B.
 
When antibodies develop, doctors may use larger doses of clotting factors or try different sources of the clotting factor. In some cases, antibodies may go away on their own. Researchers continue to study ways to deal with antibodies to clotting factors.
 

Hemophilia Treatment Risks: Viruses From Human Blood Factors

The viruses that cause AIDS (HIV) and hepatitis can be carried in clotting factors. However, there has not been a documented case of transmission of these viruses for about a decade, due to:
 
  • Careful screening of donors
  • Testing of donated blood products
  • Treating donated blood products used to create clotting factors with a detergent and heat to destroy viruses.
 
Hemophilia research scientists continue to find ways to make blood products safer.
 

Risks Associated With Delays in Receiving Hemophilia Treatment

When hemophilia treatment for bleeding is delayed, damage to the area affected (such as a joint) can occur. It is important for people with the disease to learn to recognize symptoms of hemophilia as soon as possible after bleeding starts and to get treatment quickly.

Hemophilia Disease

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.